Clinical Trial Update: Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating Rondecabtagene Autoleucel for aggressive large B-cell lymphoma in patients with relapsed or refractory Non-Hodgkin lymphoma, curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rondecabtagene Autoleucel

Snippet

Sponsor: Lyell Immunopharma, Inc. | Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING